TY  - GEN
AU  - Chen,Jinyun
AU  - Li,Donghui
AU  - Killary,Ann M
AU  - Sen,Subrata
AU  - Amos,Christopher I
AU  - Evans,Douglas B
AU  - Abbruzzese,James L
AU  - Frazier,Marsha L
TI  - Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation
SN  - 1534-4681
PY  - 2009///0430
KW  - Adenocarcinoma
KW  - genetics
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Carcinoma, Pancreatic Ductal
KW  - Chemotherapy, Adjuvant
KW  - Cisplatin
KW  - administration & dosage
KW  - Combined Modality Therapy
KW  - Cyclin-Dependent Kinase Inhibitor p16
KW  - Cyclin-Dependent Kinase Inhibitor p27
KW  - DNA-Binding Proteins
KW  - Deoxycytidine
KW  - Disease Progression
KW  - Female
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Neoadjuvant Therapy
KW  - Neoplasm Proteins
KW  - Nuclear Proteins
KW  - Pancreatic Neoplasms
KW  - Pancreaticoduodenectomy
KW  - Polymorphism, Single Nucleotide
KW  - Prognosis
KW  - Proto-Oncogene Proteins c-mdm2
KW  - Radiotherapy, Adjuvant
KW  - Survival Rate
KW  - Time Factors
KW  - Tumor Protein p73
KW  - Tumor Suppressor Proteins
KW  - Gemcitabine
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1245/s10434-008-0220-8
ER  -